Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN
About this trial
This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring ADC, Antibody drug conjugate, Tissue Factor, Auristatin, Nivolumab, Bevacizumab
Eligibility Criteria
Inclusion Criteria:
- Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.
- Dose-Escalation Stage Cohort A and AN and Cohort-Expansion Stage (Cohorts B - K, BN, FN and HN): The subject has received standard life-prolonging therapies unless they do not exist, or available therapies are intolerable or no longer effective.
- Cohort-Expansion Stage Cohort B and BN (Non-small Cell Lung Cancer): Subjects with Stage IV NSCLC who have documented radiographic disease progression during or following their last systemic anticancer therapy.
- Cohort-Expansion Stage Cohort C (Urothelial Cancer): Subjects with transitional cell histology (including renal pelvis, ureter, urinary bladder, urethra) who have documented radiographic disease progression during or following their last systemic anticancer therapy.
- Cohort-Expansion Stage Cohort D (Ovarian Cancer): Subjects with high-grade serous ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC) who have platinum-resistant disease following treatment with platinum-containing chemotherapy.
- Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with persistent, recurrent, or metastatic carcinoma of the uterine cervix who have documented radiographic disease progression during or following their last systemic anticancer therapy.
- Cohort F and FN (SCCHN): Subjects with head and neck cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Allowed primary tumor locations are oral cavity, oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects with primary tumor site of the nasopharynx.
- Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinoma histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy.
- Cohort H and HN (Esophageal SCC): Subjects with esophageal cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Note: subjects with esophageal adenocarcinoma and adenocarcinoma of gastroesophageal junction (GEJ) are excluded.
- Cohort I (mCRPC): Subjects with metastatic, castration resistant adenocarcinoma of the prostate. Note: Neuroendocrine differentiation and other histological features are permitted if adenocarcinoma is the primary histology.
- Cohort J (TNBC): Subjects with triple-negative (estrogen receptor negative [ER-]/progesterone receptor negative [PR-]/ human epidermal growth factor receptor 2 negative [HER-2-]) breast cancer who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease.
- Cohort K (HR + BC): Subjects with breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER-2-) and who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease.
- Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined by the Investigator.
- Tumor tissue material collected approximately 2 years prior to consent. If archival tumor tissue is not available, a fresh tumor biopsy may be collected from subjects enrolled in the Dose-Escalation Stage and must be collected from subjects in the Cohort-Expansion Stage, at least 7 days (and up to 60 days) prior to first dose.
- Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse Events version 5 [CTCAE v5]) from AEs.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- Adequate organ and marrow function.
- Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
- Female subjects of childbearing potential must not be pregnant at screening.
Exclusion Criteria:
- Receipt of prior therapies as defined in study protocol
- Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
- Uncontrolled, significant intercurrent or recent illness.
- Major surgery within 4 weeks before first dose of study treatment
- Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG).
- Pregnant or lactating females
- Previously identified allergy or hypersensitivity to components of study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies.
- Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.
Sites / Locations
- Exelixis Clinical Site #20Recruiting
- Exelixis Clinical Site #21Recruiting
- Exelixis Clinical Site #16Recruiting
- Exelixis Clinical Site #22Recruiting
- Exelixis Clinical Site #6Recruiting
- Exelixis Clinical Site #18Recruiting
- Exelixis Clinical Site #25Recruiting
- Exelixis Clinical Site #19Recruiting
- Exelixis Clinical Site #10Recruiting
- Exelixis Clinical Site #5Recruiting
- Exelixis Clinical Site #11Recruiting
- Exelixis Clinical Site #8Recruiting
- Exelixis Clinical Site #7Recruiting
- Exelixis Clinical Site #23Recruiting
- Exelixis Clinical Site #12Recruiting
- Exelixis Clinical Site #15Recruiting
- Exelixis Clinical Site #4Recruiting
- Exelixis Clinical Site #3Recruiting
- Exelixis Clinical Site #24Recruiting
- Exelixis Clinical Site #1Recruiting
- Exelixis Clinical Site #14Recruiting
- Exelixis Clinical Site #2Recruiting
- Exelixis Clinical Site #9Recruiting
- Exelixis Clinical Site #17Recruiting
- Exelixis Clinical Site #13Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
XB002 Single-Agent Dose-Escalation Cohorts
XB002 Single-Agent Expansion Cohorts
XB002 + Nivolumab Dose Escalation Cohorts
XB002 + Nivolumab Dose Expansion Cohorts
XB002 + Bevacizumab Dose Escalation Cohorts
XB002 + Bevacizumab Dose Expansion Cohorts
Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), ovarian cancer (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F), pancreatic cancer (Cohort G), Esophageal SCC (Cohort H), metastatic castration-resistant prostate cancer (Cohort I), triple-negative breast cancer (Cohort J), hormone-receptor positive breast cancer (Cohort K), endometrial cancer (Cohort L) and tumor agnostic tissue factor-expressing solid tumors (Cohort M).
Subjects (Cohort AN) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort BN), SCCHN (Cohort FN), Esophageal SCC (Cohort HN).
Subjects (Cohort AB) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with epithelial ovarian cancer [EOC] (Cohort DB)